Author:
Buehler Anna Maria,Flato Uri P.,Ferri Cleusa P.,Fernandes Jefferson G.
Funder
Hospital Alemao Oswaldo Cruz
Reference56 articles.
1. March 17, 2000. FDA Blood Products Advisory Committee 65th Meeting. In: FDA (Ed.). Transcript, Miller Reporting Company, Inc., Silver Spring, Maryland.
2. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%);Ballow;Vox Sang.,2003
3. The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID);Bayrakci;Turk. J. Pediatr.,2005
4. Subcutaneous immunoglobulin replacement in primary immunodeficiencies;Berger;Clin. Immunol.,2004
5. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma;Berger;J. Clin. Immunol.,2007
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献